Advertisement


Jerald P. Radich, MD, on Treatment Milestones in CML: Stay the Course or Change Therapy?

2015 NCCN Annual Conference

Advertisement

Jerald P. Radich, MD, of the Fred Hutchinson Cancer Research Center and Seattle Cancer Care Alliance discusses the evolution in treating and monitoring CML and whether monitoring at 3 and 6 months will ultimately prove useful.



Related Videos

Peter G. Shields, MD, on New NCCN Guidelines: Smoking Cessation for Patients With Cancer

Peter G. Shields, MD, of The Ohio State University Comprehensive Cancer Center and the James Cancer Hospital and Solove Research Institute, discusses the new NCCN Guidelines for helping patients with cancer to stop smoking. Counseling is a critical part of these new recommendations.

Robert W. Carlson, MD, and John A. Gentile, Jr, on Milestones of NCCN

Robert W. Carlson, MD, Chief Executive Officer, National Comprehensive Cancer Network, and John A. Gentile, Jr, Chairman, Harborside Press, LLC, discuss the early days of NCCN, controversies that surrounded the first meeting, oncologists’ embrace of the guidelines, and how the organization has evolved over the past 20 years.

Multiple Myeloma

Kenneth C. Anderson, MD, on Multiple Myeloma: Current Treatment Approaches and Future Directions

Kenneth C. Anderson, MD, of Dana-Farber/Brigham and Women’s Cancer Center, discusses the incredible progress made in treating multiple myeloma, with nine therapeutic options approved in the past decade, two drugs approved this year, and a number of new options on the horizon.

Pancreatic Cancer
Hematologic Malignancies

Samuel M. Silver, MD, PhD, and Margaret A. Tempero, MD, on Multidisciplinary Management of Pancreatic Cancer

Samuel M. Silver, MD, PhD, of the University of Michigan Comprehensive Cancer Center, and Margaret A. Tempero, MD, of the UCSF Helen Diller Family Comprehensive Cancer Center, discuss drugs developed for hematologic malignancies that have activity in pancreatic cancer, vaccines, neoadjuvant treatment, and the need to focus on activated RAS.

Cost of Care

Clifford Goodman, PhD, and Peter B. Bach, MD, MAPP, on Value-Based Decision-Making at the Bedside

Clifford Goodman, PhD, of the The Lewin Group, and Peter B. Bach, MD, MAPP, of Memorial Sloan Kettering Cancer Center, discuss the affordability of cancer care, the “financial toxicities” of high drug prices, and what could and should be done about it.

Advertisement

Advertisement



Advertisement